7.1 National Cancer Surveillance Programs: SEER & CDC NPCR

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR

Population-based cancer surveillance provides the objective empirical bedrock for cancer prevention, etiology research, healthcare resource allocation, and survivorship evaluation in the United States. Unlike hospital cancer registries—which capture cases diagnosed or treated within a single institution to optimize clinical care and hospital accreditation—central population-based cancer registries monitor all newly diagnosed malignancies occurring among residents of a designated geographic territory, regardless of where diagnosis or treatment occurs.

At the national level, United States cancer surveillance is anchored by two complementary federal initiatives: the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) and the National Program of Cancer Registries (NPCR) administered by the Centers for Disease Control and Prevention (CDC). Working in synchronized coordination with standard-setting bodies, these two surveillance pillars capture 100% of newly diagnosed cancers across the nation.

---

The NCI Surveillance, Epidemiology, and End Results (SEER) Program

The SEER program was established pursuant to the National Cancer Act of 1971 (Public Law 92-218), signed into law by President Richard Nixon, which launched the national "War on Cancer" and mandated the collection, analysis, and dissemination of cancer data in the United States. Operational data collection under SEER began on January 1, 1973, initially encompassing nine geographic registries.

Scope and Demographic Representation

Over the ensuing decades, the SEER program strategically expanded its geographic footprint to reflect the shifting demographic composition of the United States. Successive expansions—moving from SEER 9 to SEER 13, SEER 18, SEER 21, and subsequent expansion registries—were designed to intentionally oversample historically underrepresented racial, ethnic, and rural populations. Today, SEER registries cover approximately 48% of the United States population, including substantial representation of African American, Hispanic, American Indian/Alaska Native, Asian American, and Native Hawaiian/Pacific Islander communities.

The original SEER 9 registries (Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah and Atlanta) provide the longest trends. Later expansions added registries such as Los Angeles, San Jose-Monterey, rural Georgia and the Alaska Native Tumor Registry, then greater California, Kentucky, Louisiana, New Jersey and greater Georgia, and more recently additional states such as Idaho, New York, Massachusetts, Illinois and Texas. SEER's published groupings (SEER 8, 12, 17, 22 and so on) let analysts pick the longest trend or the broadest coverage.

Core Mission and Epidemiologic Focus

SEER functions as the premier biomedical research surveillance system in global oncology. Its core missions encompass:

1. Longitudinal Patient Follow-Up: SEER registries maintain active patient follow-up systems to track vital status, cause of death, and long-term relative survival rates spanning decades.
2. Specialized Biospecimen and Clinical Registries: SEER operates specialized programs such as the Residual Tissue Repository (RTR), which links annotated tumor tissue biospecimens with curated registry clinical data.
3. Rapid Response Surveillance Studies (RRSS): An agile infrastructure allowing researchers to conduct targeted patient contact, genetic subtyping studies, and quality-of-life surveys within months of initial diagnosis.
4. SEER*Stat Analytical Software: The NCI develops and distributes the standard analytical software suite used worldwide by epidemiologists to calculate incidence, mortality, relative survival, and prevalence statistics.

---

The CDC National Program of Cancer Registries (NPCR)

Despite the scientific excellence of SEER, by the early 1990s significant cancer surveillance deficits persisted across large swaths of the United States. Many states lacked central cancer registries entirely, operated under inadequate state legislative authorities, or suffered from chronic underfunding that precluded complete statewide case ascertainment. In response, Congress enacted the Cancer Registries Amendment Act of 1992 (Public Law 102-515), establishing the National Program of Cancer Registries (NPCR) under the administrative authority of the CDC Division of Cancer Prevention and Control (DCPC).

Legislative Mandates and Scope

The Cancer Registries Amendment Act authorized the CDC to provide direct financial grants and technical assistance to states and territories to establish and enhance central cancer registries. To qualify for federal NPCR funding, states were mandated to enact state-level legislation establishing:

• Mandatory reporting of cancer cases by hospitals, pathology laboratories, ambulatory surgical centers, radiation oncology clinics, and private physician practices.
• Statutory protection from liability for healthcare providers submitting required cancer records to the central registry.
• Unrestricted access for registry field abstractors to review medical records to verify complete case ascertainment.
• Strict statutory protections guaranteeing patient and facility confidentiality.

Today, NPCR funds and oversees central registries in 46 states, the District of Columbia, Puerto Rico, the United States Virgin Islands, and the Pacific Island jurisdictions. Several states—such as California, Georgia, New York, and Kentucky—receive dual funding from both SEER and NPCR for designated portions of their population or analytical activities.

Public Health and Cancer Control Mission

Whereas SEER maintains a specialized biomedical research and survival orientation, the CDC NPCR is fundamentally oriented toward public health planning, community cancer control, and health equity:

• Comprehensive Cancer Control (CCC): NPCR data serve as the direct empirical foundation for state Comprehensive Cancer Control Plans, guiding community breast and cervical cancer screening initiatives, colorectal screening expansions, and tobacco cessation programs.
• Assessing Environmental and Occupational Clusters: NPCR central registries investigate potential community cancer clusters, assess geographic disease burden, and evaluate local environmental exposures.
• Data Modernization and Electronic Pathology (e-Path): NPCR has spearheaded nationwide automated electronic reporting from commercial and hospital pathology laboratories using HL7 messaging standards.

---

Comparative Matrix: SEER vs. CDC NPCR

Understanding the operational, statutory, and functional distinctions between SEER and NPCR is essential for the Oncology Data Specialist examination:

---

Combined National Coverage & United States Cancer Statistics (USCS)

Prior to the late 1990s, the United States lacked a single, unified national publication reporting cancer incidence across the entire country. The synthesis of SEER and NPCR eliminated this historic divide. Together, SEER and NPCR capture 100% of newly diagnosed cancers across all 50 states and territories.

┌────────────────────────────────────────────────────────────────────────┐
│                     100% US Population Coverage                        │
│                                                                        │
│   ┌──────────────────────────────┐    ┌────────────────────────────┐   │
│   │        NCI SEER (~48%)       │    │      CDC NPCR (46 States,  │   │
│   │  Survival & Molecular Focus  │    │      DC & Territories)     │   │
│   └──────────────┬───────────────┘    └─────────────┬──────────────┘   │
│                  │                                  │                  │
│                  └────────────────┬─────────────────┘                  │
│                                   ▼                                    │
│                 United States Cancer Statistics (USCS)                 │
│                  Official Joint Federal Cancer Report                  │
└────────────────────────────────────────────────────────────────────────┘

The United States Cancer Statistics (USCS) Report

In 2002, the CDC and NCI published the first joint edition of United States Cancer Statistics (USCS). Published annually, USCS is the official federal report on cancer incidence and mortality. It combines registry data from both NPCR and SEER, alongside mortality data from the CDC National Center for Health Statistics (NCHS).

The 24-Month Reporting Delay Standard

A hallmark of national cancer surveillance is the standard 24-month reporting lag. For example, official cancer incidence data for diagnosis year 2024 are released in late 2026 or early 2027. This deliberate two-year interval is required to ensure:

1. Complete case ascertainment across outpatient, ambulatory surgery, and pathology venues.
2. In-depth central registry consolidation, deduplication, and cross-facility case linkage.
3. Death certificate clearance and linkage with state vital statistics.
4. Multi-tiered data quality auditing against national NAACCR standards.

---

Practice Scenario & Exam Pitfalls

Clinical Practice Scenario

A state public health department is drafting a legislative grant to expand statewide colorectal cancer screening in high-risk rural counties. The health commissioner requests cancer incidence, stage at diagnosis, and demographic disparities for every rural county across the state.

Surveillance Application: Because this project requires comprehensive statewide coverage across all 67 counties—including non-SEER rural regions—the analyst queries the state's central registry operating under CDC NPCR funding. If the project instead sought five-decade longitudinal relative survival curves with curated biobank tumor block retrieval, the analyst would partner with an NCI SEER specialized repository registry.

Core Exam Pitfalls to Avoid

• Pitfall 1: Assuming SEER covers the entire United States alone. SEER covers approximately 48% of the population via representative sampling. Complete 100% national coverage is achieved only through the combined data of SEER and NPCR.
• Pitfall 2: Confusing statutory authorities. The National Cancer Act of 1971 created SEER; the Cancer Registries Amendment Act of 1992 created the CDC NPCR. The ODS-C exam frequently tests the legislation and founding year associated with each agency.
• Pitfall 3: Misidentifying USCS governance. The United States Cancer Statistics report is not published by CDC alone or NCI alone; it is a collaborative joint federal report produced by both CDC and NCI in partnership with standard-setting organizations.